Skip to main content
This website uses cookies. By continuing to use this website you are agreeing to our use of cookies as described in our privacy policy.
Client Work

Sonus Pharmaceuticals and OncoGenex Technologies complete business combination

Fasken
Reading Time 1 minute read Subscribe
Client

OncoGenex Pharmaceuticals

On August 21, 2008, OncoGenex Pharmaceuticals, Inc. (formerly Sonus Pharmaceuticals, Inc.) (NASDAQ: OGXI) (the "Company") announced that the Company had completed its acquisition of OncoGenex Technologies and that NASDAQ had approved the commencement of trading in the Company's common stock the same day. Prior to completing the acquisition, the Company changed its name to OncoGenex Pharmaceuticals, amended its authorized share capital and effected a one-for-eighteen reverse stock split. OncoGenex Pharmaceuticals was advised in this transaction by a team from Fasken Martineau led by Iain Mant and that included, among others, Lata Casciano, Prentice Durbin and Frank Schober (tax).

    Subscribe

    Receive email updates from our team

    Subscribe